Heart failure & cardiomyopathies
Clinical Characteristics, Outcome, and Therapeutic Effect of Tafamidis in Wild-Type Transthyretin Amyloid Cardiomyopathy
Main findingResult — go to the resultHazard ratio 0.31 95% CI 0.11–0.93Authors' conclusion
The prognosis of patients with ATTRwt-CM treated with tafamidis was more favourable than that of untreated patients.
Study context
- Population
- Consecutive patients with wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM)
- Participants
- 125 vs 55
- Exposure
- Tafamidis vs no treatment
- Treatmentn = 125
- Treatment-naïven = 55reference
- Outcome
- All-cause mortality and HF hospitalization
Methodological detailssingle-centre, propensity-score matched, inverse probability of treatment weighting
- Single-centre
- Propensity-score matched
- Inverse probability of treatment weighting
Main finding
As reported in the abstract
Hazard ratio
0.31
95% CI 0.11–0.93
P = 0.04
Treatmentvs Treatment-naïve
HR 0.31 (95% CI 0.11–0.93); P = 0.04
- More favourable all-cause mortality and HF hospitalization with treatment, entire cohort
- P < 0.01
- More favourable all-cause mortality and HF hospitalization with treatment, propensity score-matched cohort
- P < 0.05
- Reduced all-cause mortality (Kaplan-Meier, log-rank), curves diverging after ≈18 months, matched cohort
- P = 0.03
Observational data: associations, not effects.
Further findings
High risk score (2-3 points: High-sensitivity cardiac troponin T (hs-cTnT) >0.05 ng/mL, BNP >250 pg/mL, estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m²) and composite of all-cause death and HF hospitalization, treatment group
| HR (95% CI) | P value | ||
|---|---|---|---|
| High score (2-3 points)Multivariate logistic regression | 1.55 (1.22–1.98) | P < 0.01 | |
| 0.512Hazard ratio (log scale) |
| Outcome | Baseline | 12 months |
|---|---|---|
| hs-cTnT, treatment group · 12 months | 0.054 (range or interval as printed 0.036–0.082) | 0.044 (range or interval as printed 0.033–0.076) |
- hs-cTnT, treatment group — hs-cTnT decreased significantly
- P = 0.002
BNP, echocardiographic parameters, native T1, extracellular volume fraction on CMR · 12 months
- No significant changes
Original publication
Clinical Characteristics, Outcome, and Therapeutic Effect of Tafamidis in Wild-Type Transthyretin Amyloid Cardiomyopathy. ESC Heart Fail. Published 18 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →